Meta-analysis: Making sense of maintenance rituximab? Paul A. Hamlin Clinical Trials Report 11 August 2009 Pages: 329 - 330
CCR9:CCL25 in melanoma metastatic to small intestine Kim A. Margolin Clinical Trials Report 11 August 2009 Pages: 331 - 332
Control of experimental melanoma by host CXCR2 Kim A. Margolin Clinical Trials Report 11 August 2009 Pages: 333 - 334
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: What is the best therapy? Alfonso Quintás-CardamaJorge Cortes OriginalPaper 11 August 2009 Pages: 337 - 345
New agents in acute myeloid leukemia: Beyond cytarabine and anthracyclines Amir T. FathiJudith E. Karp OriginalPaper 11 August 2009 Pages: 346 - 352
Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia Nitin JainNicole Lamanna OriginalPaper 11 August 2009 Pages: 353 - 359
Radioimmunotherapy: Strategies for the future in indolent and aggressive lymphoma Waleed AlduaijTim M. Illidge OriginalPaper 11 August 2009 Pages: 363 - 370
Mantle cell lymphoma: Are current therapies changing the course of disease? Christian Geisler OriginalPaper 11 August 2009 Pages: 371 - 377
The future of small molecule inhibitors in lymphoma John Gerecitano OriginalPaper 11 August 2009 Pages: 378 - 385
Second-line treatment paradigms for diffuse large B-cell lymphomas Catherine ThieblemontChristian Gisselbrecht OriginalPaper 11 August 2009 Pages: 386 - 393
Inside life of melanoma cell signaling, molecular insights, and therapeutic targets Jeffrey A. SosmanKim A. Margolin OriginalPaper 11 August 2009 Pages: 405 - 411